Larimar Therapeutics (LRMR) EBT: 2012-2019
Historic EBT for Larimar Therapeutics (LRMR) over the last 8 years, with Dec 2019 value amounting to -$45.4 million.
- Larimar Therapeutics' EBT rose 72.55% to -$3.6 million in Q1 2020 from the same period last year, while for Mar 2020 it was -$35.9 million, marking a year-over-year increase of 38.50%. This contributed to the annual value of -$45.4 million for FY2019, which is 25.68% up from last year.
- As of FY2019, Larimar Therapeutics' EBT stood at -$45.4 million, which was up 25.68% from -$61.1 million recorded in FY2018.
- In the past 5 years, Larimar Therapeutics' EBT ranged from a high of -$45.4 million in FY2019 and a low of -$74.2 million during FY2015.
- Over the past 3 years, Larimar Therapeutics' median EBT value was -$52.2 million (recorded in 2017), while the average stood at -$52.9 million.
- In the last 5 years, Larimar Therapeutics' EBT tumbled by 103.94% in 2015 and then climbed by 25.68% in 2019.
- Over the past 5 years, Larimar Therapeutics' EBT (Yearly) stood at -$74.2 million in 2015, then grew by 22.00% to -$57.9 million in 2016, then increased by 9.84% to -$52.2 million in 2017, then dropped by 17.18% to -$61.1 million in 2018, then climbed by 25.68% to -$45.4 million in 2019.